hotspot -WSS

hotspot

author：knowledge 2025-10-01 04:45:05 - browse：95285

Doctor Monica Bertagnolli, a white woman with short hair and bangs, sits at a hearing behind her name tag — coverage from STAT — National Institutes of Health Director Monica Bertagnolli testifies during her Senate HELP Committee confirmation hearing on Oct. 18 in Washington. Kevin Dietsch/Getty Images

WASHINGTON — The new National Institutes of Health director, Monica Bertagnolli, said it’s a “failure” that enrollment in government-funded clinical trials has lagged behind those funded by the pharmaceutical industry.

“If you just look at the number of patients who go on government-funded trials, it’s been completely flat over the last decade,” she said at a meeting of the advocacy group Friends of Cancer Research. “If you go and look at the number of people who go on pharma-sponsored trials, it’s just this commitment and this increase.”

A Johns Hopkins University study published in 2015 showed that the pharmaceutical industry funds six times more clinical trials than the government. Industry-sponsored trials increased 43% from 2006 to 2014, while newly registered NIH-funded trials decreased 24% over the same period.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： UpToDate has a racism problem: Dr. Stanley Goldfarb

entertainment

WSS

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Canadians with cystic fibrosis outlive Americans by a decade

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

The biotech scorecard for Q3: 15 stock

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Snackable artificial intelligence, expert AI, and the pharma industry

hotspot

hotspot

explore

Peter Hotez and the public health issue of online harassment

What affirmative action's end means to a medical student

Medicare details structure of new drug price negotiation program

Crowdfunding for unproven stem cell procedures spreads misinformation

Supreme Court strikes down use of affirmative action

Lupron, used to halt puberty in children, may cause lasting health problems

Guidelines to prevent youth baseball injuries need more muscle

Listen: Biogen's potential pivot, & Illumina's next chapter

Medical leaders decry Supreme Court decision on affirmative action

What drug price negotiations mean for Medicare Part D

explore

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Crinetics acromegaly drug succeeds in late

What drug price negotiations mean for Medicare Part D

Why Novartis is changing the name of its research labs

'Make People Better': The CRISPR babies story you probably don't know

Hubble vs. James Webb telescope images: See the difference

entertainment

hotspot

focus

explore